{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=autologous+tumor+cells&page=3",
    "query": {
      "intervention": "autologous tumor cells",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 793,
    "total_pages": 80,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=autologous+tumor+cells&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=autologous+tumor+cells&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T09:38:32.184Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05127824",
      "title": "Autologous Dendritic Cell Vaccine in Kidney Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Renal Cell"
      ],
      "interventions": [
        {
          "name": "Autologous alpha-DC1/TBVA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Jodi Maranchie",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2023-07-06",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-10-12T09:38:32.184Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05127824"
    },
    {
      "nct_id": "NCT00631072",
      "title": "In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Melanoma"
      ],
      "interventions": [
        {
          "name": "INKT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2008-02",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2017-06-09",
      "last_synced_at": "2026-10-12T09:38:32.184Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00631072"
    },
    {
      "nct_id": "NCT00058786",
      "title": "Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic B-Leukemia"
      ],
      "interventions": [
        {
          "name": "Injection of IL-2-secreting CD40L-expressing autologous B-CLL cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2002-12",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2012-05-23",
      "last_synced_at": "2026-10-12T09:38:32.184Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00058786"
    },
    {
      "nct_id": "NCT00609219",
      "title": "T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "autologous EBV specific CTLs",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 25,
      "start_date": "2001-08",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2012-10-10",
      "last_synced_at": "2026-10-12T09:38:32.184Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00609219"
    },
    {
      "nct_id": "NCT04837547",
      "title": "PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma",
        "Diffuse Intrinsic Pontine Glioma"
      ],
      "interventions": [
        {
          "name": "Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 24,
      "start_date": "2021-09-20",
      "completion_date": "2032-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-12T09:38:32.184Z",
      "location_count": 3,
      "location_summary": "Gainesville, Florida • Charlotte, North Carolina • Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04837547"
    },
    {
      "nct_id": "NCT05518032",
      "title": "Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Microsatellite Stable Colorectal Carcinoma",
        "Recurrent Colorectal Carcinoma",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Unresectable Colorectal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Therapeutic Autologous Dendritic Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-10-01",
      "completion_date": "2026-10-01",
      "has_results": false,
      "last_update_posted_date": "2024-09-26",
      "last_synced_at": "2026-10-12T09:38:32.184Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05518032"
    },
    {
      "nct_id": "NCT05144698",
      "title": "RAPA-201 Therapy of Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Small Cell and Non-small Cell Lung Cancer",
        "Head and Neck Cancer",
        "Squamous Cell Carcinoma of Oral Cavity",
        "Squamous Cell Carcinoma of Larynx",
        "Squamous Cell Carcinoma of Nasopharynx",
        "Squamous Cell Carcinoma of Other Specified Sites of Skin",
        "Malignant Melanoma",
        "Esophageal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "RAPA-201 Rapamycin Resistant T Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy Prior to RAPA-201 Therapy",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab (PD-1 Blocking Antibody)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Rapa Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2021-08-01",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-05-14",
      "last_synced_at": "2026-10-12T09:38:32.184Z",
      "location_count": 1,
      "location_summary": "Hackensack, New Jersey",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05144698"
    },
    {
      "nct_id": "NCT04634435",
      "title": "Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Biohaven Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 7,
      "start_date": "2021-10-21",
      "completion_date": "2025-01-10",
      "has_results": false,
      "last_update_posted_date": "2025-01-20",
      "last_synced_at": "2026-10-12T09:38:32.184Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04634435"
    },
    {
      "nct_id": "NCT06153797",
      "title": "A Positive Psychology Based Intervention (PATH-C) for Caregivers of HSCT Survivors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hematologic Malignancy",
        "Caregiver"
      ],
      "interventions": [
        {
          "name": "PATH-C",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2024-01-01",
      "completion_date": "2027-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-10-12T09:38:32.184Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06153797"
    },
    {
      "nct_id": "NCT00107289",
      "title": "Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma",
        "Pheochromocytoma"
      ],
      "interventions": [
        {
          "name": "iobenguane I 131",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 200,
      "start_date": "2006-05",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-10-12T09:38:32.184Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00107289"
    }
  ]
}